Share This Page
ORPHENGESIC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Orphengesic, and when can generic versions of Orphengesic launch?
Orphengesic is a drug marketed by Galt Pharms and is included in one NDA.
The generic ingredient in ORPHENGESIC is aspirin; caffeine; orphenadrine citrate. There are twenty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the aspirin; caffeine; orphenadrine citrate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ORPHENGESIC?
- What are the global sales for ORPHENGESIC?
- What is Average Wholesale Price for ORPHENGESIC?
Summary for ORPHENGESIC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 30 |
| DailyMed Link: | ORPHENGESIC at DailyMed |
Pharmacology for ORPHENGESIC
US Patents and Regulatory Information for ORPHENGESIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galt Pharms | ORPHENGESIC | aspirin; caffeine; orphenadrine citrate | TABLET;ORAL | 075141-001 | May 29, 1998 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Galt Pharms | ORPHENGESIC FORTE | aspirin; caffeine; orphenadrine citrate | TABLET;ORAL | 075141-002 | May 29, 1998 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
ORPHENGESIC Market Dynamics, Financial Trajectory, Patents, and Generic Competition
Orphengesic is a low-volume prescription analgesic and skeletal-muscle-relaxant combination containing orphenadrine citrate, aspirin, and caffeine. Its commercial position is driven by legacy prescribing, low manufacturing complexity, and limited differentiation rather than patent protection or branded promotion. Public company filings do not separately report Orphengesic revenue, and no reliable product-level sales series is available. The financial trajectory is therefore best characterized as a mature, fragmented generic-market product with limited standalone growth potential.
What is Orphengesic and how is it used?
Orphengesic combines three established active ingredients:
| Product | Orphenadrine citrate | Aspirin | Caffeine |
|---|---|---|---|
| Orphengesic | 25 mg | 385 mg | 30 mg |
| Orphengesic Forte | 50 mg | 770 mg | 60 mg |
The product is indicated for painful musculoskeletal conditions in which the analgesic effect of aspirin is combined with the skeletal-muscle-relaxant activity of orphenadrine. The combination is an older therapeutic approach and competes with single-agent muscle relaxants, nonsteroidal anti-inflammatory drugs, acetaminophen combinations, and nonpharmacologic treatment.
The product label identifies contraindications and warnings associated with aspirin, caffeine, and orphenadrine. Relevant risks include salicylate toxicity, gastrointestinal bleeding, hypersensitivity to aspirin, anticholinergic effects, urinary retention, glaucoma-related concerns, and central nervous-system effects. These safety considerations limit use in some older patients and patients receiving anticoagulants or other ulcerogenic medicines (DailyMed, n.d.).
How large is the Orphengesic market?
No authoritative public source reports U.S. Orphengesic revenue, prescription volume, market share, or net price. The product is not separately disclosed in the public filings of major pharmaceutical companies. Its market is likely small relative to branded muscle relaxants and high-volume generic products.
Commercial demand is constrained by four factors:
- The active ingredients are long-established and widely available.
- Physicians can substitute separate generic products or competing muscle relaxants.
- Orphengesic has limited brand promotion and no meaningful consumer marketing.
- Payers generally treat the product as a low-cost generic or legacy combination.
The addressable market consists primarily of prescriptions written by clinicians who prefer a fixed-dose combination or who continue legacy prescribing patterns. Demand is more likely to be stable or declining than structurally expanding.
What drives Orphengesic prescriptions?
Prescription demand can arise from:
- Acute or recurrent back pain
- Muscle spasm associated with musculoskeletal injury
- Patients already familiar with the combination
- Clinicians seeking a combination product rather than separate prescriptions
- Pharmacy substitution when the product is available at a favorable price
The product competes against cyclobenzaprine, methocarbamol, tizanidine, baclofen, carisoprodol, NSAIDs, and acetaminophen-based regimens. Many alternatives have more recognizable contemporary prescribing profiles and broader formulary visibility.
What is the financial trajectory for Orphengesic?
Orphengesic has no publicly disclosed standalone financial trajectory. Its economics are consistent with a mature generic prescription product:
| Financial factor | Likely effect on Orphengesic |
|---|---|
| Unit demand | Flat to declining |
| Pricing | Low and subject to generic competition |
| Gross margin | Dependent on manufacturing scale and supply continuity |
| Promotional spending | Minimal |
| Regulatory investment | Limited unless manufacturing or labeling changes occur |
| Revenue concentration | Potentially concentrated among a small number of suppliers |
| Growth opportunity | Low without expanded distribution or reformulation |
The main financial risk is not patent expiry. It is erosion of volume and margin caused by substitution, wholesaler demand, pharmacy purchasing behavior, and intermittent supply. A small generic supplier can generate useful niche revenue if it maintains reliable availability, but the product is unlikely to become a material contributor to a diversified pharmaceutical company.
What is the revenue exposure for manufacturers?
No public filing identifies Orphengesic sales as a material revenue category. Manufacturers generally report revenues by operating segment, geography, or broader product portfolio. A private or small generic company may have greater product-level exposure, but those figures are not normally available in SEC filings.
The product can still have strategic value because its formulation is relatively simple, the active ingredients are established, and the regulatory burden for continued supply is lower than for a new chemical entity. That value is operational rather than growth-oriented.
What patents protect Orphengesic?
The commercial formulation is based on old active ingredients and does not appear to depend on a modern, blocking patent estate. Public FDA materials do not identify a meaningful current Orange Book patent barrier associated with Orphengesic or Orphengesic Forte.
The relevant intellectual-property position is likely divided into three categories:
| IP category | Orphengesic position |
|---|---|
| Active-ingredient patents | Expired |
| Original combination patents | Expired or unavailable as practical barriers |
| Current formulation patents | No material blocking estate publicly evident |
| Method-of-use patents | No prominent current patent barrier publicly evident |
| Manufacturing know-how | Potentially relevant but difficult to assess publicly |
Because orphenadrine, aspirin, and caffeine are long-established substances, market exclusivity cannot be supported by composition-of-matter protection. Any current commercial advantage would come from manufacturing reliability, distribution, trademark recognition, or regulatory ownership rather than enforceable exclusivity.
What is the Orange Book status of Orphengesic?
The Orange Book is principally organized around approved new drug applications and abbreviated new drug applications. Product-level listing can vary by manufacturer, dosage form, and regulatory pathway. Public FDA resources do not indicate that Orphengesic has an active branded-NDA patent strategy comparable to products protected by listed patents and regulatory exclusivity.
The practical implications are:
- No apparent 30-month stay risk tied to an Orange Book Paragraph IV dispute.
- No obvious patent-based barrier to an ANDA applicant.
- No branded exclusivity period that would materially delay generic competition.
- Market access depends more on FDA application status, manufacturing compliance, and commercial supply than on patent litigation.
A DailyMed listing confirms that labeling information is available for a product but does not, by itself, establish a current patent or exclusivity position (National Library of Medicine, n.d.).
When did Orphengesic lose exclusivity?
Orphengesic’s underlying active ingredients and basic combination concept are legacy technologies. Any original patent protection would have expired many years ago. The product has no apparent remaining period of new chemical entity exclusivity, pediatric exclusivity, or meaningful orphan-drug exclusivity.
The applicable commercial conclusion is that Orphengesic is already in the post-exclusivity phase. Competition is legally permitted where an FDA-compliant product is available, although actual competition may remain limited if demand is small or manufacturing economics discourage multiple suppliers.
Which companies are challenging Orphengesic?
No prominent current Paragraph IV litigation campaign against Orphengesic is publicly associated with the product. This is consistent with the economics of a small, mature combination product. A challenger would receive limited benefit from a patent challenge when the product has no evident blocking patent estate and modest market demand.
Competition is more likely to occur through:
- ANDA approval or continued marketing of equivalent products
- Pharmacy-level substitution
- Wholesale contracting
- Private-label distribution
- Manufacturer exits and reentries
- Pricing changes during supply shortages
The principal competitive threat is therefore commercial substitution rather than litigation.
What formulation patents protect Orphengesic?
No publicly prominent formulation patent has been identified as a current barrier for the standard immediate-release combination. The formulation uses conventional oral-tablet technology. Potential formulation differentiation could involve tablet strength, excipient selection, coating, packaging, or release characteristics, but such features would need separate patent claims and commercial value.
The main formulations are:
- Orphengesic immediate-release tablets
- Orphengesic Forte immediate-release tablets
- Generic equivalents or therapeutically substitutable component regimens
A manufacturer seeking differentiation could pursue an extended-release product, lower-dose aspirin formulation, modified caffeine content, or a different delivery system. Those approaches would create a new development and regulatory program rather than extend meaningful protection for the existing product.
What generic entry risks exist for Orphengesic?
Generic-entry risk is high in legal terms and moderate in practical terms. The product has little apparent patent protection, but the limited market may not attract many entrants.
Legal entry risk
An applicant can potentially enter without confronting a significant patent estate. Any FDA application would still require conformity with applicable quality, labeling, bioequivalence, manufacturing, and pharmacovigilance requirements.
Commercial entry risk
A new entrant may face:
- Low prescription volume
- Low selling prices
- Limited wholesaler interest
- Manufacturing costs that reduce margin
- Small or volatile demand
- Competition from separate generic ingredients
The result is a market in which entry is legally accessible but commercially selective.
What manufacturing and supply barriers affect Orphengesic?
Manufacturing barriers are practical rather than technological. The product requires control of:
- Orphenadrine citrate assay and content uniformity
- Aspirin stability and hydrolysis control
- Caffeine assay
- Tablet compression and blend uniformity
- Moisture protection and packaging
- Cross-contamination controls
- Finished-product dissolution and stability
Aspirin is particularly sensitive to moisture-related degradation. A manufacturer must manage acetylsalicylic-acid stability, packaging integrity, and appropriate storage conditions. These requirements do not create strong exclusivity but can affect product availability and quality costs.
Supply risk may increase if only a few manufacturers produce the product or if active pharmaceutical ingredient procurement is concentrated. For a low-volume medicine, a single manufacturing disruption can have a disproportionate effect on market supply.
How does Orphengesic compare with competing muscle relaxants?
| Product | Primary positioning | Competitive advantage | Main limitation |
|---|---|---|---|
| Orphengesic | Fixed-dose analgesic and muscle-relaxant combination | Established combination and simple oral dosing | Legacy product, aspirin risks, limited promotion |
| Cyclobenzaprine | Broadly used muscle relaxant | High physician familiarity and generic availability | Sedation and anticholinergic effects |
| Methocarbamol | Muscle relaxant | Broad generic access and common prescribing | Limited differentiation |
| Tizanidine | Muscle spasm treatment | Mechanistic utility in selected patients | Hypotension, sedation, monitoring concerns |
| Baclofen | Spasticity treatment | Established role in neurologic spasticity | Not interchangeable for all musculoskeletal pain |
| Carisoprodol | Acute musculoskeletal pain | Familiarity in some markets | Abuse and dependence concerns |
Orphengesic’s differentiation is the fixed combination of aspirin, caffeine, and orphenadrine. That differentiation is narrow and does not provide strong pricing power.
What is the litigation and settlement outlook?
No material current patent litigation or settlement agreement is publicly associated with Orphengesic. The absence of visible litigation is commercially significant: the product does not appear to generate the type of revenue or patent leverage that usually supports ANDA settlement negotiations.
Potential disputes would more likely involve:
- Trademark ownership
- Labeling or promotional claims
- Manufacturing compliance
- Product quality
- Distribution rights
- Supply agreements
These issues would affect individual suppliers rather than create market-wide exclusivity.
How strong is the Orphengesic patent estate?
The patent estate is weak as a commercial protection mechanism. Its principal strengths are the maturity of the formulation and the established regulatory pathway. Its weaknesses are the absence of meaningful composition-of-matter protection, limited formulation differentiation, low switching costs, and the availability of competing therapies.
| Patent-estate criterion | Assessment |
|---|---|
| Composition-of-matter protection | None of practical current value |
| Combination-product protection | Expired or not commercially blocking |
| Formulation protection | No material public barrier identified |
| Method-of-use protection | No material public barrier identified |
| Regulatory exclusivity | No meaningful current exclusivity identified |
| Manufacturing know-how | Possible, but not publicly quantifiable |
| Litigation leverage | Low |
Key Takeaways
- Orphengesic is a mature combination of orphenadrine citrate, aspirin, and caffeine.
- Public sources do not provide standalone revenue or prescription data.
- Its financial profile is likely small, stable to declining, and dependent on supply reliability rather than market expansion.
- The product has no apparent meaningful current patent or regulatory exclusivity barrier.
- Paragraph IV litigation and settlement risk appear low.
- Generic-entry risk is legally high but commercially moderated by limited demand.
- The main competitive threats are generic substitution, alternative muscle relaxants, and separate-ingredient prescribing.
- Manufacturing quality, aspirin stability, distribution, and product availability are more important than patent strength.
- Orphengesic is unlikely to represent material revenue exposure for a diversified pharmaceutical company unless held by a small supplier with concentrated portfolio economics.
FAQs
Is Orphengesic still available by prescription?
Availability depends on manufacturer, dosage strength, wholesaler inventory, and pharmacy distribution. The product has been marketed as an oral prescription tablet, including Orphengesic and Orphengesic Forte strengths.
Is Orphengesic a controlled substance?
Orphengesic is not generally classified as a controlled substance under the federal Controlled Substances Act. Its orphenadrine component can still cause sedation, anticholinergic effects, and misuse concerns in clinical practice.
Can aspirin and orphenadrine be prescribed separately?
Yes. Separate generic products may be used when clinically appropriate, although the dosage, tolerability, prescribing instructions, and reimbursement profile may differ from the fixed-dose combination.
Does Orphengesic have biosimilar competition?
No. Orphengesic is a small-molecule oral combination product, not a biologic. The relevant competition is from generic drugs and therapeutic alternatives, not biosimilars.
Is Orphengesic a viable product for pharmaceutical licensing?
It may have niche value in an established generic portfolio with manufacturing and distribution infrastructure. Its limited demand, low differentiation, and weak patent protection make it unattractive as a standalone licensing asset unless the transaction includes a broader product portfolio or supply agreement.
References
DailyMed. (n.d.). Orphengesic Forte: Orphenadrine citrate, aspirin, and caffeine tablet. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
National Library of Medicine. (n.d.). DailyMed drug label database. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/daf/
More… ↓
